Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05954871
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Christiana Care Health System, Newark, Delaware, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 420
- Registration Number
- NCT05948813
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT05816252
- Locations
- 🇦🇺
St Vincent's Hospital - Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT05801029
- Locations
- 🇹🇭
Research Site, Songkhla, Thailand
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 287
- Registration Number
- NCT05785741
- Locations
- 🇺🇸
Research Site 111, Atlanta, Georgia, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-03-27
- Target Recruit Count
- 122
- Registration Number
- NCT05785208
- Locations
- 🇮🇹
Università degli Studi di Verona, Verona, Italy
🇮🇹Ospedale San Luigi, Turin, Italy
🇮🇹IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05693090
- Locations
- 🇺🇸
The Valley Hospital, Ridgewood, New Jersey, United States
🇺🇸Providence Medical Group, Santa Rosa, California, United States
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-01-17
- Target Recruit Count
- 65
- Registration Number
- NCT05686434
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
First in Human Study of AZD9592 in Solid Tumors
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 162
- Registration Number
- NCT05647122
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.